Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index

Leukemia Research

Volumn 36, Issue 4, 2012, Pages

  Breccia, Massimo ^a   Loglisci, Giuseppina ^a   Salaroli, Adriano ^a   Serrao, Alessandra ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; IMATINIB; NILOTINIB;

ADULT; AGE DISTRIBUTION; AGED; BODY MASS; CHRONIC MYELOID LEUKEMIA; COMORBIDITY; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; LETTER; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX RATIO;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOOD GLUCOSE; BODY MASS INDEX; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERGLYCEMIA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PYRIMIDINES; YOUNG ADULT;

EID: 84857234082     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.12.011     Document Type: Letter

References (9)

1. Breccia M., Muscaritoli M., Gentilini F., et al. Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. Leuk Res 2007, 31:1765-1772.
2. le Coutre P., Giles F.J., Hochhaus A., et al. Analysis of glucose profiles in imatinib-resistant or intolerant chronic myelogenous leukemia (CML) patients treated with nilotinib: lack of correlation between glucose levels and nilotinib efficacy. Blood 2007, 110. abstr 4588.
3. Breccia M., Alimena G. The metabolic consequences of imatinib mesylate: changes on glucose, lypidic and bone metabolism. Leuk Res 2009, 33:871-875.
4. Breccia M., Muscaritoli M., Aversa Z., Mandelli F., Alimena G. Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment. J Clin Oncol 2004, 22:4653-4655.
5. Hagerkvist R., Janssson L., Weish N. Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet. Clin Sci (London) 2008, 114:65-71.
6. Mokhtari D., Welsh N. Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes. Clin Sci (Lond) 2009, 118:241-247.
7. Aichberger K.J., Herndlhofer S., Schernthaner G.H., et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011, [Epub ahead of print].
8. Day E., Waters B., Spiegel K., et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol 2008, 599:44-53.
9. Saglio G., Larson R.A., Hughes T.P., et al. Efficacy and safety of nilotinib in chronic phase (CP) chronic myeloid leukemia (CML) patients (pts) with type 2 diabetes in the ENESTnd trial. Blood 2010, 116. abstr 3430.